Percheron Therapeutics Limited (ASX:PER)

Australia · Delayed Price · Currency is AUD

0.0040

-0.0010 (-20.00%)

Oct 1, 2026, 2:04 PM AEST

Market Cap	7.29M -33.0%
Revenue (ttm)	843.60K -53.2%
Net Income	-4.79M
EPS	-0.00
Shares Out	1.82B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,519,399
Open	0.0050
Previous Close	0.0050
Day's Range	0.0040 - 0.0050
52-Week Range	0.0020 - 0.0110
Beta	1.10
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About Percheron Therapeutics

Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 ... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2000

Employees 8

Stock Exchange Australian Securities Exchange

Ticker Symbol PER

Full Company Profile

Financial Performance

In fiscal year 2026, Percheron Therapeutics's revenue was 843,600, a decrease of -53.16% compared to the previous year's 1.80 million. Losses were -4.79 million, -67.89% less than in 2025.

Financial Statements